ATE264692T1 - Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie - Google Patents

Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie

Info

Publication number
ATE264692T1
ATE264692T1 AT97940183T AT97940183T ATE264692T1 AT E264692 T1 ATE264692 T1 AT E264692T1 AT 97940183 T AT97940183 T AT 97940183T AT 97940183 T AT97940183 T AT 97940183T AT E264692 T1 ATE264692 T1 AT E264692T1
Authority
AT
Austria
Prior art keywords
caughters
reactive oxygen
synthase inhibitors
oxygen forms
treat ischemia
Prior art date
Application number
AT97940183T
Other languages
English (en)
Inventor
De Lassauniere Pierre Chabrier
Denis Bigg
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE264692T1 publication Critical patent/ATE264692T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97940183T 1996-09-06 1997-09-05 Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie ATE264692T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9610875A FR2753098B1 (fr) 1996-09-06 1996-09-06 Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
PCT/FR1997/001567 WO1998009653A1 (fr) 1996-09-06 1997-09-05 Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene

Publications (1)

Publication Number Publication Date
ATE264692T1 true ATE264692T1 (de) 2004-05-15

Family

ID=9495505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940183T ATE264692T1 (de) 1996-09-06 1997-09-05 Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie

Country Status (14)

Country Link
US (1) US6297281B1 (de)
EP (1) EP0939654B1 (de)
JP (1) JP2000517336A (de)
AT (1) ATE264692T1 (de)
AU (1) AU734296B2 (de)
CA (1) CA2264901C (de)
DE (1) DE69728782T2 (de)
ES (1) ES2221066T3 (de)
FR (1) FR2753098B1 (de)
IL (1) IL128801A (de)
NO (1) NO991100L (de)
NZ (1) NZ334597A (de)
RU (1) RU2174844C2 (de)
WO (1) WO1998009653A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017998A1 (en) * 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1068868A3 (de) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistischer Zusammensetzung, der Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeneration
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
DE69911212T2 (de) * 1998-07-10 2004-07-15 Duke University Anwendung der hemoproteine in der therapie
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9827393D0 (en) * 1998-12-11 1999-02-03 Univ London Treatment of erectile dysfunction in diabetes patients
FR2787447B1 (fr) 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
EP1013272A1 (de) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Beeinflussung der Aktivität eines Stickoxidradikalherstellungsweges zur Behandlung von mit freien Sauerstoffradikalen verbundenen Krankheiten
US6075045A (en) * 1999-04-28 2000-06-13 Ajinomoto Co., Inc. Method of treating paralysis of the extremities caused by cerebral infarction
DE19962267A1 (de) * 1999-12-23 2001-06-28 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
EP1808169B8 (de) * 1999-12-30 2012-07-04 Proteotech Inc. Polyhydroxylierte aromatische Verbindungen zur Behandlung von Amyloidose und $g(a)-Synuklein-Fibrillen-Erkrankungen
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
DE10000840A1 (de) * 2000-01-12 2001-07-19 Beiersdorf Ag Verwendung eines oder mehrerer NO-Synthasehemmer
EP1353664A2 (de) * 2000-06-08 2003-10-22 The Board Of Regents, The University Of Texas System Heterocycle derivaten und verwendungen zur behandlung von anthrax infektionen
WO2001095897A1 (en) * 2000-06-15 2001-12-20 University Of Kentucky Research Foundation Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
KR100849999B1 (ko) 2000-09-05 2008-08-01 메디터 파마슈티칼스 리미티드 두통, 편두통, 구역질 및 구토를 위한 약학적 조성물
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
CH694549A5 (de) 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
DE10111054A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
DE10111049A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111052A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10219644A1 (de) * 2002-05-02 2003-11-20 Johannes Wohlrab Verwendung vom Agmatin zur topischen Applikation
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
GB0214147D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Formulations
CA2499549C (en) * 2002-10-11 2012-01-24 Proteotech, Inc. Isolation, purification and synthesis of procyanidin b2 and uses thereof
US20090186929A1 (en) * 2003-11-10 2009-07-23 U.S. Department Of Veterans Affairs Method and agent for inducing apoptosis/cell death in leukemia cells
US20050234026A1 (en) * 2003-11-10 2005-10-20 Weinberg Joe B Method and agent for inducing apoptosis/cell death in leukemia cells
NZ548212A (en) 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
AU2005257982B8 (en) * 2004-06-16 2011-03-10 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US8283327B2 (en) 2005-03-19 2012-10-09 Kneller Bruce W Palatinose for enhancing dietary supplement and pharmaceutical delivery
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
US20090149481A1 (en) * 2005-07-04 2009-06-11 Tokyo Medical And Dental University Pharmaceutical composition and beverage composition comprising l-arginine
EP1986636B1 (de) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol- und 1,4-benzochinon-derivate zur verwendung in der behandlung von erkrankungen der mitochondrien
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
EP2344142B1 (de) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Behandlung von pervasiven entwicklungsstörungen mit redox-aktiven therapeutika
EP2273273A1 (de) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer
NO2470168T3 (de) * 2009-08-26 2018-06-30
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP3389646A1 (de) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouralkyl, flouralkoxy, phenoxy, heteroaryloxy, alkoxy und amin-1,4-benzochinon-derivate zur behandlung von oxidativen stresserkrankungen
CN119054693B (zh) * 2024-07-17 2025-09-12 中国农业科学院麻类研究所 一种芥子酸植物生长调节剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320484D0 (en) * 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
AU1209995A (en) * 1993-11-17 1995-06-06 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
DE69425287T2 (de) * 1994-11-15 2001-03-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger

Also Published As

Publication number Publication date
DE69728782D1 (de) 2004-05-27
AU4211197A (en) 1998-03-26
NO991100L (no) 1999-05-05
NO991100D0 (no) 1999-03-05
IL128801A (en) 2005-05-17
US6297281B1 (en) 2001-10-02
FR2753098A1 (fr) 1998-03-13
EP0939654A1 (de) 1999-09-08
IL128801A0 (en) 2000-01-31
CA2264901A1 (fr) 1998-03-12
RU2174844C2 (ru) 2001-10-20
ES2221066T3 (es) 2004-12-16
EP0939654B1 (de) 2004-04-21
FR2753098B1 (fr) 1998-11-27
CA2264901C (fr) 2006-01-03
NZ334597A (en) 2000-10-27
WO1998009653A1 (fr) 1998-03-12
DE69728782T2 (de) 2005-04-28
JP2000517336A (ja) 2000-12-26
AU734296B2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
ATE299015T1 (de) Hautpflegemitteln enthaltend eine kombination von aktive wirkstoffen
EP1014961A4 (de) Verbesserter behandlung von migränekopfschmerzen
AP9901478A0 (en) Compounds for the treatment of ischemia.
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
EP1015008A4 (de) Verbindungen und zusammensetzungen zur administration aktiver stoffe
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200001203T2 (tr) Yeni birleşik maddeler
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
EA199800772A1 (ru) Производные 6-фенилпиридил-2-амина
ATE253892T1 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
DK1001775T3 (da) Medikament indeholdende yohimbin og arginin beregnet til behandling af erektil dysfunktion
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE338768T1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
TR199901237T2 (xx) Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�.
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties